Obesity News

A novel oral GLP-1 receptor agonist was well-tolerated and linked with weight loss compared with placebo in healthy adults with overweight or obesity, according to top-line results of a phase 1 study.

The FDA has cleared a tubeless automated insulin delivery system indicated for adults with type 2 diabetes.

Results from two studies found no association between the use of GLP-1 receptor agonists and increased risk for suicide, suicidal thoughts or depression, findings published in JAMA Internal Medicine showed.

In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone reduced risk for CV death and worsening HF by 16% compared with placebo, researchers reported at the European Society of Cardiology Congress.

In an analysis of deaths of patients with obesity but not diabetes from the SELECT trial, those assigned semaglutide 2.4 mg had reduced risk for death from COVID-19 compared with those assigned placebo.

Managing obesity involves a well-rounded approach, often including lifestyle modifications and, in many cases, pharmacotherapy. Understanding the role of anti-obesity medications is crucial in this context.

Researchers estimate that semaglutide 2.4 mg is not cost-effective for secondary CVD prevention for patients with overweight or obesity without diabetes, according to an Australian study.

Asian American, Native Hawaiian and Pacific Islander, or AA and NH/PI, communities continue to face significant racial disparities in health care access and outcomes across the United States, according to an expert.

Adults with obesity who have been prescribed tirzepatide can now purchase 2.5 mg and 5 mg single-dose vials of the medication, Eli Lilly announced.

High BMI eligibility for semaglutide could cost Medicare up to $145 billion annually, a brief report published in the Annals of Internal Medicine revealed.